Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 116Radiotherapy 84Paclitaxel 77Fluorouracil 62Carboplatin 41Drug Therapy 38pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26Neoadjuvant Therapy 24Oxaliplatin 23toripalimab 22sintilimab 19camrelizumab 19Radiation 19Esophagectomy 18Capecitabine 17130-nm albumin-bound paclitaxel 17Surgical Procedures, Operative 16Nivolumab 16Leucovorin 15Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10Immune Checkpoint Inhibitors 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × bryostatin 1 × Gastrointestinal × Clear all
NCT00005599 2013-06-21

Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡